Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine

Jing Chen, Kusuma Gopala, P K Akarsh, Frank Struyf, Dominique Rosillon, Jing Chen, Kusuma Gopala, P K Akarsh, Frank Struyf, Dominique Rosillon

Abstract

Objective: Data on human papillomavirus (HPV) prevalence around pregnancy were inconsistent. We assessed HPV prevalence before and after pregnancy, HPV incidence after pregnancy, and risk factors for HPV infection.

Method: Data from 15 754 women in control arms of 5 AS04-HPV-16/18 vaccine efficacy trials were analyzed, including 3001 women with at least 1 pregnancy. Results of HPV deoxyribonucleic acid testing on cervical samples were available. We analyzed risk factors, including age, region, pregnancy and its outcomes, duration from pregnancy resolution to collection of first postresolution cervical sample, previous HPV infection, cigarette smoking, and number of sexual partners with Cox regression.

Results: Prevalence of high-risk oncogenic (hr)-HPV types was similar before and after pregnancy (20.8% vs 19.8%). Incidence of hr-HPV was 40.1 per 1000 person-years (95% confidence interval [CI], 23.4-64.2) at 0-3 months, 266.7 (95% CI, 217.4-323.7) at 3-6 months, and 95.7 (95% CI, 83.9-108.7) at >6 months after pregnancy. Risk factors associated with HPV infection after pregnancy are previous HPV infection, elective abortion, and younger age at pregnancy resolution.

Conclusions: Pregnancy could not be confirmed as a risk factor for HPV infection in this population despite an increased incidence detected 3-6 months after pregnancy resolution. Most women remained HPV negative after pregnancy.

Clinical trial registration: NCT001226810 (HPV-008 trial), NCT00294047 (HPV-015 trial), NCT00316693 and NCT00929526 (HPV-032/063 trials), and NCT00779766 (HPV-039 trial).

Trial registration: ClinicalTrials.gov NCT00316693 NCT01226810 NCT00779766 NCT00294047 NCT00929526 NCT00316693 NCT01226810 NCT00779766 NCT00294047 NCT00929526.

Keywords: human papillomavirus; incidence; pregnancy; prevalence; risk factor.

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

References

    1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244–65.
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359–86.
    1. Bruni L, Barrionuevo-Rosas L, Albero G, et al. . Human Papillomavirus and Related Diseases in the World. . Published July 27, 2017. Accessed November 22, 2018.
    1. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006; 12:S462–72.
    1. Moscicki AB. HPV infections in adolescents. Dis Markers 2007; 23:229–34.
    1. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16 563 women with cervical carcinoma and 33 542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006; 119:1108–24.
    1. Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer 2013; 108:234–9.
    1. Muñoz N, Franceschi S, Bosetti C, et al. ; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359:1093–101.
    1. Sappenfield E, Jamieson DJ, Kourtis AP. Pregnancy and susceptibility to infectious diseases. Infect Dis Obstet Gynecol 2013; 2013:752852.
    1. Liu P, Xu L, Sun Y, Wang Z. The prevalence and risk of human papillomavirus infection in pregnant women. Epidemiol Infect 2014; 142:1567–78.
    1. Salcedo MM, Damin AP, Agnes G, et al. . Prevalence of human papillomavirus infection in pregnant versus nonpregnant women in Brazil. Arch Gynecol Obstet 2015; 292:1273–8.
    1. Schmeink CE, Melchers WJ, Hendriks JC, et al. . Human papillomavirus detection in pregnant women: a prospective matched cohort study. J Womens Health (Larchmt) 2012; 21:1295–301.
    1. Trottier H, Mayrand MH, Baggio ML, et al. ; Ludwig-McGill Cohort Study Group Risk of human papillomavirus (HPV) infection and cervical neoplasia after pregnancy. BMC Pregnancy Childbirth 2015; 15:244.
    1. Massad LS, Einstein MH, Huh WK, et al. ; 2012 ASCCP Consensus Guidelines Conference 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17:S1–S27.
    1. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018; 5:CD009069.
    1. Harper DM, DeMars LR. HPV vaccines - a review of the first decade. Gynecol Oncol 2017; 146:196–204.
    1. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. . Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016; 4:e453–63.
    1. Apter D, Wheeler CM, Paavonen J, et al. ; HPV PATRICIA Study Group Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol 2015; 22:361–73.
    1. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010; 20:847–55.
    1. Konno R, Yoshikawa H, Okutani M, et al. . Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother 2014; 10:1781–94.
    1. Skinner SR, Szarewski A, Romanowski B, et al. ; VIVIANE Study Group Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014; 384:2213–27.
    1. Zhu FC, Chen W, Hu YM, et al. ; HPV-039 study group Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer 2014; 135:2612–22.
    1. Zhu FC, Hu SY, Hong Y, et al. . Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Med 2017; 6:12–25.
    1. Lehtinen M, Paavonen J, Wheeler CM, et al. ; HPV PATRICIA Study Group Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89–99.
    1. Paavonen J, Jenkins D, Bosch FX, et al. ; HPV PATRICIA Sudy Group Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161–70.
    1. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44:3292–8.
    1. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. . High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum. Br J Cancer 2002; 87:75–80.
    1. Chan PK, Chang AR, Tam WH, et al. . Prevalence and genotype distribution of cervical human papillomavirus infection: comparison between pregnant women and nonpregnant controls. J Med Virol 2002; 67:583–8.
    1. Jawed-Wessel S, Sevick E. The impact of pregnancy and childbirth on sexual behaviors: a systematic review. J Sex Res 2017; 54:411–23.
    1. Leeman LM, Rogers RG. Sex after childbirth: postpartum sexual function. Obstet Gynecol 2012; 119:647–55.
    1. Sok C, Sanders JN, Saltzman HM, Turok DK. Sexual behavior, satisfaction, and contraceptive use among postpartum women. J Midwifery Womens Health 2016; 61:158–65.
    1. Castellsagué X, Paavonen J, Jaisamrarn U, et al. ; HPV PATRICIA Study Group Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infect Dis 2014; 14:551.
    1. Chang SR, Chen KH, Lin HH, Yu HJ. Comparison of overall sexual function, sexual intercourse/activity, sexual satisfaction, and sexual desire during the three trimesters of pregnancy and assessment of their determinants. J Sex Med 2011; 8:2859–67.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel